The following abstracts showcase the top cutting-edge research presented at the European Society for Medical Oncology (ESMO) ...

77-year-old patient with squamous NSCLC who had previously received carboplatin plus ... We recently presented encouraging efficacy and safety data at ESMO on NUC-7738 plus pembrolizumab in patients ...

Announced encouraging initial Phase 2 data of BDTX-1535 in patients with recurrent EGFRm NSCLC with a broad spectrum of classical, non-classical, ...

Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today reported financial results for the third quarter ...

The metastatic non-small cell lung cancer (mNSCLC) treatment landscape has vastly expanded over the past two decades as a ...

Merus’ zenocutuzumab is nearing FDA approval, and petosemtamab shows promise. Learn why MRUS stock could rise as the company ...

CStone Pharmaceuticals (HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that the UK Medicines and ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved the medicine sugemalimab (trade name Eqjubi) to treat adult patients with a type of cancer called non-small cell lung ...

The results of the GALAXIES Lung-02 study reported at the ESMO congress in Barcelona showed ... or metastatic PD-L1-high (50% or greater) NSCLC that could not be treated with surgery.

another key risk is that the 2025 expansion cohort update in ovarian cancer could see a similar "sell the news" reaction to this year's ESMO data. One more concern is that I'm not sure the NSCLC ...

WILMINGTON, Del., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage ...

An expert discussed how liquid and tissue biopsies can help monitor treatment and detect potential resistance in patients ...